Diabetes and Peripheral Vascular Disease

References

• VINIK A., Flemmer M. Diabetes and macrovascular disease. J Diabetes Complications, 2002, 16: 235–245.
   Google Scholar
• Mohler E. 3rd. Therapy insight: peripheral arterial disease and diabetes: from pathogenesis to treatment guidelines. Nat Clin Pract Cardiovasc Med, 2007, 4: 151–162.
   Google Scholar
• American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care, 2003, 26: 3333–3341.
   Google Scholar
• American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care, 2003, 42: 3333–3341.
   Google Scholar
• Adler A., Stevens R., Neil A., Stratton I., Boulton A., Holman R. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care, 2002, 25: 894–899.
   Google Scholar
• Marso S., Hiatt R. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol, 2006, 47: 921–929.
   Google Scholar
• Rein P., Beer S., Saely Ch., Vonbank A., Drexel H. Prevalence of impaired glucose metabolism in individuals with peripheral arterial disease. Int J Cardiol, 2009 Feb 2. (Epub ahead of print).
   Google Scholar
• Rahman S., Rahman T., Ismail A. A., Rashid A. R. Diabetes-associated macrovasculopathy: pathophysiology and pathogene-sis. Diabetes Obes Metab, 2007, 9: 767–780.
   Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med, 1993, 329: 977–986.
   Google Scholar
• Nathan D. M., Lachin J., Cleary P. et al. Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med, 2003, 348: 2294–2303.
   Google Scholar
• Cleary P., Orchard T., Zinman B. et al. Coronary calcification in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes, 2003, 52: Suppl 2: A152.abstract.
   Google Scholar
• Nathan D., Cleary P., Backlund J. et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353: 2643–2653.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes. Lancet, 1998, 352: 837–853.
   Google Scholar
• Stratton I., Adler A., Neil H. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321: 405–412.
   Google Scholar
• Holman R. R, Paul S. K, Bethel M. A, Matthews D. R, Neil H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359: 1577–1589.
   Google Scholar
• Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008, 358: 2560–2572.
   Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes (Accord) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358: 2545–2559.
   Google Scholar
• Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009, 360: 129–139.
   Google Scholar
• Ewing D., Boland O., Neilson J. et al. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia, 1991, 34: 182–185.
   Google Scholar
• Desouza C., Salazar H., Cheong B., Murgo J., Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care, 2003, 26: 1485–1489.
   Google Scholar
• Wright R. J., Frier B. M. Vascular disease and diabetes: is hypo-glycaemia an aggravating factor? Diabetes Metab Res Rev, 2008, 24: 353–363.
   Google Scholar
• Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348: 383–393.
   Google Scholar
• Gaede P., Lund-Andersen H., Parving H. H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008, 358: 580–591.
   Google Scholar
• Heikkinen M., Salmenperä M., Lepäntalo A., Lepäntalo M. Diabetes care for patients with peripheral arterial disease. Eur J Vasc Endovasc Surg, 2007, 33: 583–591.
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1944, 344: 1383–1389.
   Google Scholar
• Colhoun H. M., Betteridge D. J., Durrington P. N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative AtoRvastatin Diabetes Study (CARDS). Lancet, 2004, 364: 685–696.
   Google Scholar
• Heart Protection Study Collaborative Group: Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg, 2007, 45: 645–654.
   Google Scholar
• Howard B. V., Roman M. J., Devereux R. B. et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA, 2008, 299: 1678–1689.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ, 1998, 31: 703–713.
   Google Scholar
• Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342: 145–153.
   Google Scholar
• Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy in prevention of death, myocardial infarction, and stroke, by prolonged antiplatelet therapy in various categories of patients. Br Med J, 1994, 308: 81–106.
   Google Scholar
• CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet, 1996, 348: 1329–1339.
   Google Scholar
• Bhatt D. L, Marso S. P, Hirsch A. T, Ringleb P. A, Hacke W., Topol E. J. Amplified benefits of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol, 2002, 90: 625–628.
   Google Scholar
• American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2009, 32: S62–S67.
   Google Scholar